Traumatic brain injury (TBI) is an environmental risk factor for Alzheimer's disease (AD). Increased brain concentrations of amyloid-b (Ab) peptides and impaired cerebral blood flow (CBF) are shared pathologic features of TBI and AD and promising therapeutic targets. We used arterial spin-labeling magnetic resonance imaging to examine if CBF changes after TBI are influenced by human Ab and amenable to simvastatin therapy. CBF was measured 3 days and 3 weeks after controlled cortical impact (CCI) injury in transgenic human Ab-expressing APP NLh/NLh mice compared to murine Ab-expressing C57Bl/6J wild types. Compared to uninjured littermates, CBF was reduced in the cortex of the injured hemisphere in both Ab transgenics and wild types; deficits were more pronounced in the transgenic group, which exhibited injury-induced increased concentrations of human Ab. In the hemisphere contralateral to CCI, CBF levels were stable in Ab transgenic mice but increased in wild-type mice, both relative to uninjured littermates. Post-injury treatment of Ab transgenic mice with simvastatin lowered brain Ab concentrations, attenuated deficits in CBF ipsilateral to injury, restored hyperemia contralateral to injury, and reduced brain tissue loss. Future studies examining longterm effects of simvastatin therapy on CBF and chronic neurodegenerative changes after TBI are warranted.
INTRODUCTION
Traumatic brain injury (TBI) is the leading cause of morbidity and mortality in the developed world's working-age population. The burden of severe TBI on the health-care system is exacerbated by increased incidence of Alzheimer's disease (AD) in long-term survivors of TBI 1 and lack of effective therapies for either disorder.
Several neuropathologic parallels link TBI with AD.These include reduced cerebral blood flow (CBF) and increased brain concentrations of amyloid-b (Ab) peptide; both are potential therapeutic targets. Deficits in CBF are associated with poorer neurologic outcome after TBI 2 and are posited to contribute to increased risk of developing AD. 3 Accumulation of Ab, the principal component of toxic soluble oligomers and fibrillar aggregates in plaques and cerebral vasculature in AD brains, 4 is observed after human TBI [5] [6] [7] and after experimental TBI. [8] [9] [10] [11] [12] Brain accumulation of Ab may be due to injury-induced changes in amyloidogenic (Ab-producing) processing of the amyloid precursor protein (APP), changes in enzymatic degradation of Ab, or alterations in receptors involved in Ab trafficking and clearance, all of which may be potentiated by brain hypoxia resulting from CBF deficits. The potent vasoactive effects of Ab [13] [14] [15] may, in turn, result in further reductions in CBF, resulting in a vicious cycle of changes in CBF and Ab peptide accumulation. These observations, together with the wellcharacterized pathologic role of Ab in TBI and AD, 16 warrant identification of therapies with the dual effect of reducing injury or disease-induced pathologic concentrations of Ab and restoring normal levels of CBF. Ideally, such therapies would have wellcharacterized beneficial effects on central nervous system structure and function in models of neuronal insult, without harmful side effects.
There are currently no effective treatments for improved recovery and long-term rehabilitation of survivors of TBI, in part owing to lack of clinically relevant experimental models of TBI (particularly those that model TBI-induced increased risk for AD), and the high target specificity of most tested therapies. 17 To directly address these issues, the purpose of this investigation was twofold: (1) to examine the CBF alterations in a preclinical murine model of brain trauma-induced elevations in brain concentrations of human Ab (APP NLh/NLh human Ab knock-in mouse model 10 ) , and (2) to examine the therapeutic effect of the FDA-approved drug, simvastatin, on brain trauma-induced changes in CBF in the same model. Simvastatin was identified as a promising therapeutic candidate because of its beneficial effects in a wide variety of brain injury models (reviewed in Wible and Laskowitz 18 ), and more specifically owing to its Abreducing and other beneficial effects on histologic and behavioral outcomes after TBI in APP NLh/NLh mice, 10 and its beneficial effects on CBF in Ab precursor protein (APP)-overexpressing transgenic mouse models of AD. 19, 20 
MATERIALS AND METHODS Animal Model and Experimental Groups
All experiments were approved by the Animal Care and Use Committees of the University of Pittsburgh and Carnegie Mellon University. Male APP NLh/NLh C57Bl/6J (n ¼ 43; referred to as APP NLh/NLh ) and wild-type C57Bl/ 6J (n ¼ 23; Charles River; referred to as C57) mice (aged 100-150 days) were used in these investigations. The APP NLh/NLh mouse has the human Ab coding sequence 'knocked-in' to the murine APP gene (using site-based mutagenesis), and has the Swedish FADK670N/M671L mutation, which results in production of detectable levels of human Ab. 21 Unlike traditional APP transgenic mouse models, APP NLh/NLh mice do not overexpress APP, as the APP gene is under the control of its endogenous promoter. Concentrations of human Ab peptides are amenable to experimental manipulation 9, 10 and are detectable by a sensitive human, but not murine, specific enzyme-linked immunosorbent assay. 9, 10 Mice were maintained on a 12-hour light-dark cycle with free access to food and water before experimentation. Separate experimental groups included (1) naive (wild-type C57); (2) naive (APP NLh/NLh ); (3) controlled cortical impact (CCI), 3-day survival (wild-type C57); (4) CCI, 3-day survival (APP NLh/NLh ), (5) CCI, 3-week survival (wild-type C57); (6) CCI, 3-week survival (APP NLh/NLh ). The simvastatin intervention experiment was performed on APP NLh/NLh mice only; groups consisted of CCI followed by a 3-week survival with either vehicle or simvastatin treatment.
Controlled Cortical Impact
Mice were subjected to CCI as described previously. 10 Briefly, anesthesia was induced with 3% isoflurane in N 2 O/O 2 (1:1; Baxter Pharmaceutical Products, Deerfield, IL, USA) and mice were maintained on 1% to 2% isoflurane for the duration of the surgical procedure (approximately 30 minutes). Mice were placed on a heating pad in a stereotaxic apparatus and an approximately 5-mm-diameter craniotomy was performed over the left parietal-temporal cortex. Body temperature was monitored by a rectal probe (Physitemp Instruments, Clifton, NJ, USA). Mice were subjected to vertically directed CCI (stereotaxic coordinates of the center of the impactor tip relative to Bregma: AP ¼ -2.0; ML ¼ þ 1.5) using a pneumatic cylinder (Bimba, Monee, IL, USA) with a 3-mm flat-tip impactor at a velocity of 4 m/s, and a depth of 1 mm, using a driving pressure of 73 psi. Immediately after injury, the bone flap was replaced, sealed with Koldmount cement (Vernon Benshoff, Albany, NY, USA), and the scalp closed. Isoflurane was then discontinued and mice were allowed to recover from anesthesia in an oxygen hood for 30 minutes. Mice were then returned to their cages, where they remained under daily observation during the duration of this study.
Simvastatin Administration
Mice were administered simvastatin (3 mg/kg body weight, determined to be an effective dose in this experimental paradigm 10 ) dissolved in 3% methylcellulose by oral gavage starting 3 hours after CCI injury and once daily thereafter for the duration of the experiment (3 weeks).
Magnetic Resonance Imaging Protocol
Naive mice and injured mice (3 days or 3 weeks after CCI) were intubated and mechanically ventilated with 2% isoflurane and N 2 O/O 2 (1:1). Physiologic measures, including temperature, blood pressure, and blood gasses, were continuously monitored and adjusted (if necessary) to ensure there were no differences in these variables between groups. A femoral artery catheter was inserted surgically for continuous blood pressure monitoring and arterial blood sampling. Temperature was maintained at 37.0 ± 0.51C using a warm air heating system (SA Instruments, New York, NY, USA). Mean arterial blood pressure and heart rate were also monitored throughout image acquisition. Arterial blood gases were collected at the beginning and end of the studies; ventilator rate and tidal volume were adjusted to maintain an arterial CO 2 tension (PaCO 2 ) of 30-45 mm Hg. Mice were considered out of protocol and excluded from the study if the final PaCO 2 measurement was outside this range. Mice were placed onto a cradle in the prone position, and the head was secured with ear bars and an adjustable bite bar to limit motion.
MR studies were performed as described previously 22 on a 4.7-T, 40-cmbore Bruker AVANCE system (Billerica, MA, USA), equipped with a 12-cmdiameter shielded gradient insert and a home-built saddle-type RF coil. Image acquisition parameters were identical to those reported previously. 22 Briefly, T 2 -weighted images were acquired with the following parameters: field of view 2.5 cm, 1 mm slice thickness, TR/TE ¼ 2500/40 milliseconds, two averages, five slices, and a 128 Â 70 matrix interpolated to 128 Â 128. Perfusion studies were performed using continuous arterial spin labeling and spin-echo sequence with the following parameters: 64 Â 40 matrix interpolated to 64 Â 64, TR ¼ 2000 milliseconds, summation of three echoes, TE ¼ 10, 20, and 30 milliseconds, and two averages. The labeling pulse for the inversion plane was positioned ± 2 cm from the perfusion detection plane. Spin-labeling efficiency was determined from intensities within the carotid arteries using a gradient echo sequence, with a 451 flip angle, eight averages, TR/TE ¼ 100/9.6 milliseconds, 256 Â 256 matrix, and spin labeling applied at ±6 mm. The spin-lattice relaxation time of tissue water (T 1obs ) was measured from a series of spin-echo images with variable TR values of 8,000, 4,300, 2,300, 1,200, 650, 350, 185, and 100 milliseconds.
Cerebral Blood Flow Image Analysis
Regions of interest (ROIs) included the left (ipsilateral to injury) and right (contralateral to injury) hemispheres and the cortex, cortical contusion region (CR), hippocampus, thalamus, and the amygdala/piriform cortex within each hemisphere in the coronal plane approximately 2 mm caudal to Bregma 23 (Figure 1 ). Cortical ROIs were drawn to include the entire cortex within each hemisphere (cortex), or an area beginning 1 mm from midline to the midpoint of the arc of the cortex (cortical contusion region; Figure 1 ). Pixel by pixel maps of (M C -M L )M C À 1 were generated from the perfusion data, where M C is the signal intensity from the control image and M L is the signal intensity from the labeling image. T 1obs maps were generated from the series of variable TR images. Regional CBF was then calculated from:
where l is the blood-brain partition coefficient of water, assuming a spatially constant value of 0.9 mL/g, and a is the spin-labeling efficiency measured in the arteries. ROIs were segmented from each CBF map and histograms were generated for each time point and genotype.
Ex Vivo Magnetic Resonance Image Acquisition
After in vivo MRI evaluation, the mice were perfused and brains processed using the histologic analysis protocol described below. The fixed brains were imaged using an 11.7-T, 89-mm-bore Bruker AVANCE spectrometer, equipped with a Micro 2.5 gradient insert. High-resolution 3D images were acquired with the following parameters: TR ¼ 500 milliseconds, TE ¼ 6 milliseconds, FOV ¼ 1 Â 1 Â 1.7 cm 3 , four averages, with an approximate isotropic resolution of 40 mm. Lesion size was assessed in eight planes through the brain lesion. Percent tissue loss was determined for the whole hemisphere, as the anatomic resolution of the MRI precluded accurate measurements of the hippocampus.
Histologic Assessment of Brain Lesion Size
For histologic analyses, mice were anesthetized with 5% isoflurane in O 2 / NO 2 (1:1) and transcardially perfused with 0. Ab ELISA For biochemical assays of brain Ab content, mice were anesthetized and transcardially perfused with phosphate-buffered saline. The brain was extracted and immediately dissected on ice, and the hippocampus and cortex ipsilateral and contralateral to injury were isolated, snap frozen in liquid nitrogen, and stored at -801C until assayed. Frozen brain tissues were sonicated on ice in 0.2% diethylamine and 150 mmol/L NaCl with a protease inhibitor cocktail consisting of 1 mmol/L AEBSF, 0.8 mmol/L aprotinin, 20 mmol/L leupeptin, 40 mmol/L bestatin, 15 mmol/L pepstatin A, and 14 mmol/L E-64, and centrifuged at 135 000 g for 1 hour. Levels of human Ab1-40 and Ab1-42 were assayed in diethylamine-soluble supernatant, using TMB-based enzyme-linked immunosorbent assay (Invitrogen) as described previously. 9 Ab values are expressed as femtomoles Ab per gram tissue wet weight.
Statistical Analysis
All data are expressed as mean±standard deviation. Independent C57 and APP NLh/NLh mice were studied for each time point (naive, 3 days, and 3 weeks). Data from C57 and APP NLh/NLh were compared at each time point using a two-tailed Student's t-test. A probability of less than 0.05 (Po0.05) was considered significant.
RESULTS
Physiology Parameters and Baseline Regional CBF There were no differences in arterial blood gasses, hematocrit, blood glucose, blood pH, or mean arterial blood pressure between groups of injured and uninjured (naive) C57 or APP NLh/NLh mice, and injured APP NLh/NLh mice administered simvastatin or vehicle (Table 1 ).
In naive C57 and APP NLh/NLh mice, CBF values were comparable in the brain regions examined (Figures 2 and 3) . In both C57 and APP NLh/NLh mice, CBF was highest in the thalamus (251.5±23.3 and 251.5 ± 45.6 mL per 100 g per minute, respectively) and lowest in the amygdala (157.0 ± 23.9 and 164.7 ± 34.5 mL per 100 g per minute, respectively).
Regional CBF Changes 3 Days and 3 Weeks After CCI Injury
CBF ipsilateral to injury (3 days). Compared to the naive groups, CBF values in injured C57 and APP NLh/NLh mice were similarly reduced in the cortex and the cortical CR ipsilateral to injury (Po0.05 compared with naive). CBF values in the thalamus of the injured C57 group were higher than in the C57 naive group (Po0.05). CBF in the thalamus of the injured APP NLh/NLh group was not significantly different from the APP NLh/NLh naive group, but was lower than in the injured C57 group (Po0.05; Figures 2 and 3) .
CBF contralateral to injury (3days). The injured C57 group had higher CBF values in the hemisphere and thalamus (Po0.05), Abbreviations: CCI, controlled cortical impact; MABP, mean arterial blood pressure; veh, vehicle; WT, wild type. Data were collected before and after perfusion imaging and averaged. All variables were within normal range. and in the amygdala, cortex, and in the cortical CR (corresponding to the contusion region on the side of the injury; Po0.01), compared to naive C57 controls. CBF in the hemisphere and thalamus of the injured APP NLh/NLh group was lower than in the injured C57 group (Po0.05; Figures 2 and 3 ) and did not differ the naive APP NLh/NLh group.
CBF ipsilateral to injury (3 weeks). Compared to naive groups, injured C57 and APP NLh/NLh groups had lower CBF values in the cortex and cortical CR (Po0.05, with the exception of the C57 cortex, which did not reach statistical significance). The injured APP NLh/NLh group had lower CBF values in the cortex and thalamus (Po0.05) and in the hemisphere and cortical CR (Po0.01) when compared with the injured C57 group (Figure 3) .
CBF contralateral to injury (3 weeks). The injured C57 group had higher CBF values in the amygdala (Po0.05), and in the hemisphere, thalamus, cortex, and the cortical CR (Po0.01) when compared with naive groups. CBF values in the injured APP NLh/NLh group were lower in the cortex and cortex CR (Po0.05) and in the hemisphere and amygdala (Po0.01) compared with the injured C57 group (Figure 3 ) and did not differ in any region compared with the APP NLh/NLh naïve group.
Effect of simvastatin therapy on CBF after CCI injury in APP NLh/NLh mice (3 weeks). We next examined the effects of postinjury treatment with simvastatin (3 mg/kg daily by oral gavage) or vehicle on CBF in APP NLh/NLh mice 3 weeks after CCI injury. Compared with vehicle-treated APP NLh/NLh mice, simvastatintreated APP NLh/NLh mice had significantly higher CBF values bilaterally in the thalamus and in the contralateral cortical CR region compared with vehicle-treated APP NLh/NLh mice (Po0.05; Figure 4 ). There was a trend for higher CBF in the ipsilateral hippocampus and the contralateral cortex and amygdala in the simvastatin group compared with the vehicle group (Figure 4 ).
Effects of simvastatin therapy after CCI: relation to lesion volume and brain Ab concentration in APP NLh/NLh mice (3 weeks). By ex vivo MR imaging, APP NLh/NLh mice treated with simvastatin had significantly greater brain tissue sparing compared with vehicle-treated APP NLh/NLh mice (Po0.05; Figures 5A and 5B) . These observations were confirmed by histologic examination of tissue sections of the same brains ( Figures 5C and 5D ), although the simvastatintreatment-associated increase in tissue sparing did not reach statistical significance. Diethylamine-soluble Ab peptides were not detectable in C57 mice, and were detected in all APP NLh/NLh brain samples; Ab1-40 was consistently higher than Ab1-42. CCI injury resulted in increases in both Ab species in the hippocampus and cortex ipsilateral and contralateral to injury relative to the naive group ( Figure 6 ). Injured, simvastatin-treated APP NLh/NLh mice had lower hippocampal and cortical Ab levels bilaterally compared with injured, vehicle-treated APP NLh/NLh mice (Po0.05) except for the ipsilateral hippocampus ( Figure 6 ). Significantly lower Ab levels correlated with higher CBF in the contralateral cortex and cortex CR; however, this relationship was not observed in the ipsilateral cortex and cortex CR, where CBF levels remained unchanged relative to vehicle-treated mice despite significant regional reductions in Ab levels. There was no relationship between Ab concentrations and CBF levels bilaterally in the hippocampus. There were no differences in Ab42/40 ratios between groups (not shown). Over all measured regions, there was a trend for an inverse relation between Ab concentration (summed Ab40 and Ab42) and CBF in the contralateral cortex (r ¼ À 0.63; P 2 ¼ 0.092).
DISCUSSION
The present study demonstrates regional differences in CBF after CCI injury modified by genetic introduction of human Ab peptides (APP NLh/NLh mice) and simvastatin therapy. Brain injury-induced reductions in CBF were observed in the ipsilateral cerebral cortex and cortical CR of wild-type C57 mice, and were exacerbated in APP NLh/NLh (human Ab-producing) mice, particularly at longer time points (3 weeks) after injury. In contrast, brain regions contralateral to injury exhibited increased CBF in injured, wild-type C57 mice, with regional and temporal patterns similar but opposite of what was observed in the ipsilateral cortex and cortical CR; these contralateral increases in CBF were blunted in injured APP NLh/NLh mice. Regional variation in CBF alterations after CCI injury may be the result of different injury and reparative processes in areas subjected to direct mechanical injury and necrotic cell death (e.g., cortex including the contusion region) compared with the hippocampus and thalamus (and the hemisphere contralateral to CCI injury), which are characterized by secondary injury processes such as glial activation, production of cytokines and reactive oxygen species, and apoptosis, which may result in, or be enhanced in, areas of increased energy utilization. 24 Alternatively, increased CBF in the contralateral hemisphere may result from compensatory or disinhibition processes occurring in response to disrupted neural connectivity. Postinjury hyperemia is observed in humans, particularly in areas of brain tissue without overt damage. 25 Hyperemia is attenuated in aged animals, 26 and may be a necessary condition for recovery from TBI. 2 However, whether CCI injury-induced hyperemia represents CBF dysregulation or a beneficial reactive response to CCI injury in the current model is unknown.
Exacerbated CBF deficits and blunted hyperemia responses after CCI in APP NLh/NLh compared with C57 mice may be due to the observed increases in concentrations of human Ab, a neurotoxic peptide with potent vasoactive properties. APP NLh/NLh mice exhibited blunted increases in CBF in brain regions contralateral to CCI injury compared with C57 wild types, reminiscent of Ab-associated attenuation of functional hyperemia in mouse neocortex. 27 Soluble human Ab may act as a potent vasoconstrictor and modulator of CBF through enhancement of endothelin-1 vasoconstriction, stimulation of proinflammatory pathways involving 5-lipoxygenase and cyclooxygenase-2, release of free radicals (reviewed in Iadecola 3 and Townsend et al 28 ) , and impairment of angiogenesis. 29 In transgenic AD mice overexpressing mutant human Ab-precursor protein (APP), decreases in CBF and impairment of cerebrovascular autoregulation are proportional to brain Ab levels. 30 These observations suggest that therapeutics, such as simvastatin, that lower Ab in conditions of brain injury and have complementary CBF-modifying effects have promising clinical potential regardless of the connection between Ab and CBF, which is likely complex and not amenable to dissection and resolution in in vivo models of TBI.
We observed modulatory effects of simvastatin administration on CCI injury-induced changes in CBF and Ab levels in CCI-injured APP NLh/NLh mice; attenuated deficits in CBF were observed in brain regions ipsilateral to injury and restored hyperemia was observed in brain regions contralateral to injury. CBF-modifying effects of simvastatin treatment after TBI and in other models of impaired CBF were observed previously 19, 20, 31 and are likely due to the drug's pleiotropic mechanisms of action, including upregulation of endothelial nitric oxide synthase (NOS) with subsequent elevations in NO, 32, 33 and reduced production of isoprenoid intermediates in the cholesterol synthesis pathway (reviewed in Laufs and Liao 34 ). Simvastatin administration was also reported to associate with 'augmented angiogenesis' after experimental TBI, particularly in the lesion boundary zone, 35 angiogenesis in mediating the effects of simvastatin on CBF in the current model is less clear, especially in brain areas distal to the area of mechanical lesion (i.e., lesion boundary zone). Hamel and colleagues 19, 20 reported restorative effects of simvastatin on CBF responses to neuronal activation in an uninjured, APPoverexpressing mouse AD model, with parallel reductions in oxidative stress, inflammation, and monomeric Ab. Simvastatin therapy is also associated with reductions in inflammatory markers in several brain injury models, 36 including the model used in the current experiment; 10 these studies report reductions in activated microglia, particularly relevant to current hypotheses linking TBI, microglia activation, and increased Ab production (reviewed in Mannix and Whalen 37 ). The current report extends these studies by demonstrating that the restorative effects of simvastatin therapy on CBF after TBI occur in parallel with reductions in physiologically soluble Ab monomers and oligomers in a clinically relevant model of mice expressing human Ab. Consistent with our previous report, 10 CCI injury in APP NLh/NLh mice resulted in sustained elevations in human Ab peptides bilaterally in the hippocampus and cortex, which, with the exception of the ipsilateral hippocampus, were suppressed by simvastatin treatment. The mechanisms connecting simvastatin treatment and changes in brain Ab concentration are likely a combination of direct effects on Ab production, degradation, or clearance and other, indirect, pathways including reduced microglia activation. 10 CBF was significantly increased in the contralateral cortical CR concomitant with reduced Ab levels. However, we observed only a weak inverse correlation between Ab concentrations and CBF levels exclusively in the contralateral cortex. Lack of correlation between these variables could be reflective of a complex relationship between biochemical and in vivo imaging measures or other, non-Ab-related injury responses superimposed on the known vasoactive effects of Ab. Alternatively, Ab oligomers may correlate more closely with CBF changes; this may be masked by our enzyme-linked immunosorbent assay protocol, which does not distinguish between Ab monomers and oligomers. This may also explain the large variability in hippocampal Ab concentrations, which were not affected by simvastatin ipsilateral to injury. Although this investigation does not prove, nor was it designed to prove, a direct relationship between simvastatin-induced reductions in brain Ab and associated positive effects on CBF and histologic outcome, the results of this investigation and the previously discussed preclinical reports provide strong rationale for using simvastatin in clinical TBI therapy trials. Furthermore, the nearly unparalleled success of simvastatin in preclinical intervention trials in multiple types of neurologic insult, its safety and tolerance in humans (established over 420 years of use in humans), and studies indicating its therapeutic potential in the treatment of human neurologic disorders overwhelmingly support the therapeutic potential of simvastatin.
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